Pliaglis Generic Name & Formulations
Lidocaine 7%, tetracaine 7%; emulsion cream.
Topical anesthetic (amide-type + ester-type).
Local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, laser-assisted tattoo removal).
Pliaglis Dosage and Administration
Do not exceed recommended dose or duration. Apply to intact skin prior to procedure; spread evenly and thinly across treatment area using a metal spatula or tongue depressor. Dermal filler inj or facial laser ablation: apply for 20–30mins. Laser-assisted tattoo removal: apply for 60mins. Amount (length) to apply: see full labeling.
Pliaglis Boxed Warnings
Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Avoid overexposure. Severe hepatic disease. Pseudocholinesterase deficiency. Risks of secondary exposure to children and pets; may be toxic. Avoid contact with eyes, mucous membranes, or areas with a compromised skin barrier (eg, broken or inflamed). Acutely ill. Debilitated. Elderly. Pregnancy. Nursing mothers.
Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others. Toxicity may be potentiated by Class I antiarrhythmics (eg, tocainide, mexiletine); caution. Additive effects with other products containing local anesthetics; consider the amount absorbed from all formulations.
Pliaglis Adverse Reactions
Localized reactions (eg, erythema, skin discoloration, edema), allergic reactions (eg, urticaria, angioedema, bronchospasm, shock).
Pliaglis Clinical Trials
Pliaglis Patient Counseling